SUPER Shredder

SUPER Shredder — The Ultimate Elite Peptide Fat Loss Stack for Maximum Lipolysis, Thermogenesis, Appetite Suppression, and Lean Muscle Preservation

SUPER Shredder is the most comprehensive and aggressively formulated peptide-based fat loss stack available for serious body composition research and performance enhancement. Engineered for individuals who demand maximum results from their cutting phase, SUPER Shredder combines a precisely selected matrix of synergistic peptide and pharmacological compounds — each chosen for its distinct and complementary mechanism of action — to simultaneously attack body fat from every metabolic angle. By targeting lipolysis, thermogenesis, appetite suppression, metabolic rate elevation, and lean muscle preservation through multiple independent pathways at once, SUPER Shredder delivers a magnitude of fat loss and body composition improvement that no single compound can achieve alone. This is not a standard fat burner. This is an elite, science-driven shredding protocol built for those who take their physique and performance research to the highest level.

What Is the SUPER Shredder Stack?

SUPER Shredder is a multi-compound synergistic fat loss stack formulated around the most clinically validated and potent lipolytic, thermogenic, and appetite-suppressing peptides and compounds available in research and performance pharmacology. The stack is designed on the principle of metabolic redundancy — by simultaneously activating multiple independent fat loss pathways, SUPER Shredder eliminates the adaptive resistance that the body develops when only a single mechanism is targeted. When the body attempts to compensate for one fat loss stimulus by down-regulating a single pathway, the other active mechanisms in the stack continue to drive fat mobilisation and energy expenditure uninterrupted.

The components of SUPER Shredder are selected and dosed based on published clinical and preclinical data to ensure that each contributes meaningfully to the overall fat loss outcome while complementing rather than duplicating the mechanisms of the other stack members. The result is a precisely orchestrated metabolic assault on adipose tissue that operates across the full spectrum of fat loss physiology: from central appetite regulation and reward pathway modulation, to peripheral lipolysis in adipocytes, brown adipose thermogenesis, and hormonal optimisation for lean mass preservation.

SUPER Shredder Stack Components and Their Mechanisms

Retatrutide — Triple Receptor Agonist for Maximum Appetite Suppression and Fat Oxidation

At the foundation of SUPER Shredder’s fat loss architecture sits Retatrutide — the most powerful incretin-based compound ever evaluated in clinical trials. As a triple GLP-1, GIP, and glucagon receptor agonist, Retatrutide operates through three complementary metabolic pathways simultaneously. GLP-1 receptor activation delivers profound appetite suppression by dramatically lowering hunger signals in the hypothalamus and slowing gastric emptying. GIP receptor activation enhances insulin sensitivity and modulates adipose tissue fat metabolism. Glucagon receptor activation — the component that no other GLP-1 or dual agonist provides — drives thermogenesis in brown adipose tissue and accelerates hepatic fat mobilisation and fatty acid oxidation. In Phase 2 clinical trials, Retatrutide produced mean weight loss of up to 24.2% of total body weight at 48 weeks — the greatest weight loss magnitude ever recorded in a pharmaceutical trial — establishing it as the cornerstone lipolytic compound in the SUPER Shredder stack.

Tesofensine — Central Appetite Crusher and Metabolic Rate Amplifier

Tesofensine, the triple monoamine reuptake inhibitor that simultaneously elevates serotonin, dopamine, and noradrenaline in the central nervous system, provides SUPER Shredder with its most powerful centrally-acting appetite suppression mechanism. By flooding hypothalamic satiety centres with elevated monoaminergic tone, Tesofensine dramatically reduces hunger, blunts cravings for high-calorie foods, and suppresses reward-driven eating behaviour through dopaminergic modulation of the mesolimbic pathway. Simultaneously, its noradrenergic sympathomimetic component increases resting metabolic rate by stimulating beta-3 adrenoceptors in brown adipose tissue — directly elevating thermogenesis and 24-hour energy expenditure. In the Phase 2 TIPO-1 trial, Tesofensine at 500mcg daily produced 12.8% mean weight loss in 24 weeks through this dual mechanism. Within the SUPER Shredder stack, Tesofensine’s central mechanism is entirely complementary to Retatrutide’s peripheral incretin-based actions — together they suppress appetite from both central monoaminergic and peripheral hormonal angles simultaneously.

AOD-9604 — The Fat-Specific Lipolytic Growth Hormone Fragment

AOD-9604 is a modified fragment of the C-terminal region of human growth hormone — specifically amino acids 176-191 — engineered to retain GH’s lipolytic fat-burning activity while eliminating its insulin-like effects on blood glucose and cellular proliferation. AOD-9604 directly stimulates lipolysis in adipocytes through beta-3 adrenergic receptor activation and inhibits lipogenesis — the conversion of dietary carbohydrates and excess energy into new fat stores. Its highly targeted fat-specific mechanism makes it an ideal complement to SUPER Shredder’s appetite-suppressing compounds: while Retatrutide and Tesofensine reduce the flow of new calories into the system, AOD-9604 accelerates the burning of existing fat stores at the cellular level. AOD-9604 operates without suppressing the hypothalamic-pituitary axis — making it a clean, targeted lipolytic agent that adds a direct fat cell mechanism to the stack’s multi-pathway approach.

SUPER Shredder Stack Components and Their Mechanisms

Retatrutide — Triple Receptor Agonist for Maximum Appetite Suppression and Fat Oxidation

At the foundation of SUPER Shredder’s fat loss architecture sits Retatrutide — the most powerful incretin-based compound ever evaluated in clinical trials. As a triple GLP-1, GIP, and glucagon receptor agonist, Retatrutide operates through three complementary metabolic pathways simultaneously. GLP-1 receptor activation delivers profound appetite suppression by dramatically lowering hunger signals in the hypothalamus and slowing gastric emptying. GIP receptor activation enhances insulin sensitivity and modulates adipose tissue fat metabolism. Glucagon receptor activation — the component that no other GLP-1 or dual agonist provides — drives thermogenesis in brown adipose tissue and accelerates hepatic fat mobilisation and fatty acid oxidation. In Phase 2 clinical trials, Retatrutide produced mean weight loss of up to 24.2% of total body weight at 48 weeks — the greatest weight loss magnitude ever recorded in a pharmaceutical trial — establishing it as the cornerstone lipolytic compound in the SUPER Shredder stack.

Tesofensine — Central Appetite Crusher and Metabolic Rate Amplifier

Tesofensine, the triple monoamine reuptake inhibitor that simultaneously elevates serotonin, dopamine, and noradrenaline in the central nervous system, provides SUPER Shredder with its most powerful centrally-acting appetite suppression mechanism. By flooding hypothalamic satiety centres with elevated monoaminergic tone, Tesofensine dramatically reduces hunger, blunts cravings for high-calorie foods, and suppresses reward-driven eating behaviour through dopaminergic modulation of the mesolimbic pathway. Simultaneously, its noradrenergic sympathomimetic component increases resting metabolic rate by stimulating beta-3 adrenoceptors in brown adipose tissue — directly elevating thermogenesis and 24-hour energy expenditure. In the Phase 2 TIPO-1 trial, Tesofensine at 500mcg daily produced 12.8% mean weight loss in 24 weeks through this dual mechanism. Within the SUPER Shredder stack, Tesofensine’s central mechanism is entirely complementary to Retatrutide’s peripheral incretin-based actions — together they suppress appetite from both central monoaminergic and peripheral hormonal angles simultaneously.

AOD-9604 — The Fat-Specific Lipolytic Growth Hormone Fragment

AOD-9604 is a modified fragment of the C-terminal region of human growth hormone — specifically amino acids 176-191 — engineered to retain GH’s lipolytic fat-burning activity while eliminating its insulin-like effects on blood glucose and cellular proliferation. AOD-9604 directly stimulates lipolysis in adipocytes through beta-3 adrenergic receptor activation and inhibits lipogenesis — the conversion of dietary carbohydrates and excess energy into new fat stores. Its highly targeted fat-specific mechanism makes it an ideal complement to SUPER Shredder’s appetite-suppressing compounds: while Retatrutide and Tesofensine reduce the flow of new calories into the system, AOD-9604 accelerates the burning of existing fat stores at the cellular level. AOD-9604 operates without suppressing the hypothalamic-pituitary axis — making it a clean, targeted lipolytic agent that adds a direct fat cell mechanism to the stack’s multi-pathway approach.

mechanism. The result is sustained fat loss that maintains its momentum across a full research cycle. The synergy between these mechanisms means each component enhances the effectiveness of the others: elevated GH increases adipocyte sensitivity to AOD-9604’s lipolytic signal, while Tesofensine’s noradrenergic thermogenesis is amplified by Retatrutide’s glucagon receptor brown adipose tissue activation.

Body Recomposition — Simultaneous Fat Loss and Muscle Preservation

SUPER Shredder’s inclusion of the CJC-1295 and Ipamorelin GH axis component elevates it from a pure weight loss stack to a genuine body recomposition protocol. True body recomposition — simultaneously losing fat and preserving lean muscle mass — requires both a fat loss stimulus and an anabolic, muscle-preserving signal. Without GH and IGF-1 axis support, the aggressive caloric deficit created by Retatrutide and Tesofensine could result in lean muscle catabolism alongside fat loss — an outcome that undermines metabolic health, physical performance, and aesthetic quality. SUPER Shredder ensures this does not happen by maintaining anabolic GH and IGF-1 signalling throughout the entire cutting protocol.

Suggested Research Protocol and Dosage Guidelines

The following dosage framework is based on published clinical data and established research community protocols for each component:

• Retatrutide: 2–4mg subcutaneous injection once weekly; escalate from 1mg over first 4 weeks to minimise GI adjustment
• Tesofensine: 500mcg oral capsule once daily in the morning
• AOD-9604: 300mcg subcutaneous injection once daily, morning fasted or pre-workout
• CJC-1295 (no DAC): 100mcg subcutaneous injection 2–3 times daily; timed around training and before sleep
• Ipamorelin: 200mcg subcutaneous injection 2–3 times daily; co-administered with CJC-1295
• Melanotan II: 0.5–1mg subcutaneous injection once daily; begin at 0.25mg to assess tolerance
• Cycle Length: 8–12 weeks with appropriate rest periods and post-cycle assessment
• Monitoring: Track body weight, body fat percentage, lean mass, appetite, and energy levels weekly

Who Is SUPER Shredder Designed For?

The SUPER Shredder stack is designed for:

• Advanced researchers and performance enthusiasts targeting aggressive body recomposition
• Individuals who have plateaued on single-compound fat loss protocols needing a true multi-mechanism approach
• Athletes preparing for competition requiring simultaneous fat loss and lean mass preservation
• Research programmes investigating synergistic peptide stack interactions in metabolic and body composition studies

Why Choose Our SUPER Shredder Stack?

Every component in the SUPER Shredder stack is independently verified for purity, identity, and potency before inclusion. We source only pharmaceutical-grade or research-grade active compounds, confirmed by third-party HPLC and mass spectrometry analysis, to ensure the extraordinary synergy designed into SUPER Shredder is delivered without compromise from any single underperforming component.

Our Quality Promise Across Every Component

• Every peptide and compound independently verified at ≥98% purity by third-party HPLC
• Correct molecular identity confirmed by mass spectrometry for each stack component
• GMP-aligned manufacturing and sterile lyophilization for all injectable compounds
• Tamper-evident sealed packaging with batch number traceability and CoA on request
• Cold-chain compatible shipping protecting peptide integrity throughout transit
• Discreet, professional worldwide shipping with full tracking
• Expert customer support with comprehensive knowledge of each stack component

Frequently Asked Questions About SUPER Shredder

Can SUPER Shredder be used without prior peptide experience?

SUPER Shredder is an advanced multi-compound research stack incorporating several potent pharmacological agents and is not designed for first-time peptide researchers. Each component carries its own pharmacological activity, side-effect profile, and administration requirements. Researchers new to peptide protocols are strongly advised to gain familiarity with individual compounds — beginning with simpler stacks such as CJC-1295 and Ipamorelin — before progressing to a multi-compound stack of SUPER Shredder’s complexity and potency. A thorough review of each component’s published literature is essential before commencing a SUPER Shredder research protocol.

How does SUPER Shredder prevent muscle loss during aggressive fat loss?

Muscle preservation during aggressive fat loss is achieved through the CJC-1295 and Ipamorelin component, which stimulates sustained elevated GH and IGF-1 levels that maintain anabolic signalling necessary for muscle protein synthesis even during a caloric deficit. Growth hormone directly inhibits protein catabolism, promotes fat utilisation as the primary fuel source over lean tissue, and supports nitrogen balance in muscle fibres. This GH axis support is the critical differentiator that makes SUPER Shredder a true body recomposition stack — ensuring weight lost is primarily adipose tissue, not hard-earned lean muscle.

What results can be expected within the first 4 weeks?

Within the first four weeks, most research subjects experience a marked reduction in appetite and food cravings as the combined appetite-suppressing mechanisms of Retatrutide, Tesofensine, and Melanotan II reach their full pharmacodynamic effect. Measurable reductions in body weight — typically 2 to 5 kg depending on starting body composition and adherence — are commonly reported by weeks three and four. Energy levels and motivation for physical activity typically improve as Tesofensine’s monoaminergic components and CJC-1295 and Ipamorelin’s GH axis stimulation establish their full effects. The most dramatic and sustained fat loss results accumulate progressively across the full 8 to 12 week research cycle.